Taken together, these findings indicate that Fgfr3+ endosteal stem cells develop aggressive osteosarcoma-like lesion upon p53 tumor suppressors through unregulated self-renewal and aberrant osteogenic fates. The gene discussed is TP53; the disease is osteosarcoma.